全文获取类型
收费全文 | 20295篇 |
免费 | 1130篇 |
国内免费 | 196篇 |
专业分类
耳鼻咽喉 | 284篇 |
儿科学 | 361篇 |
妇产科学 | 318篇 |
基础医学 | 3299篇 |
口腔科学 | 438篇 |
临床医学 | 1773篇 |
内科学 | 3778篇 |
皮肤病学 | 728篇 |
神经病学 | 1640篇 |
特种医学 | 996篇 |
外科学 | 2889篇 |
综合类 | 64篇 |
一般理论 | 4篇 |
预防医学 | 801篇 |
眼科学 | 592篇 |
药学 | 1836篇 |
中国医学 | 241篇 |
肿瘤学 | 1579篇 |
出版年
2023年 | 131篇 |
2022年 | 428篇 |
2021年 | 698篇 |
2020年 | 359篇 |
2019年 | 525篇 |
2018年 | 574篇 |
2017年 | 497篇 |
2016年 | 724篇 |
2015年 | 953篇 |
2014年 | 1127篇 |
2013年 | 1207篇 |
2012年 | 1861篇 |
2011年 | 1749篇 |
2010年 | 1088篇 |
2009年 | 906篇 |
2008年 | 1241篇 |
2007年 | 1215篇 |
2006年 | 1043篇 |
2005年 | 987篇 |
2004年 | 763篇 |
2003年 | 630篇 |
2002年 | 583篇 |
2001年 | 349篇 |
2000年 | 327篇 |
1999年 | 245篇 |
1998年 | 101篇 |
1997年 | 78篇 |
1996年 | 59篇 |
1995年 | 72篇 |
1994年 | 41篇 |
1993年 | 27篇 |
1992年 | 93篇 |
1991年 | 86篇 |
1990年 | 90篇 |
1989年 | 77篇 |
1988年 | 75篇 |
1987年 | 55篇 |
1986年 | 57篇 |
1985年 | 51篇 |
1984年 | 34篇 |
1983年 | 34篇 |
1981年 | 28篇 |
1980年 | 23篇 |
1979年 | 39篇 |
1978年 | 48篇 |
1977年 | 26篇 |
1976年 | 20篇 |
1975年 | 31篇 |
1974年 | 35篇 |
1973年 | 21篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. 总被引:1,自引:0,他引:1
Onset of the mitochondrial permeability transition (MPT) causes both necrotic and apoptotic cell death in cultured hepatocytes. Salicylate lowers the threshold for onset of the MPT. In this study, our aim was to determine whether nontoxic concentrations of salicylate potentiate MPT-mediated cell killing. In necrotic killing models to rat hepatocytes, salicylate (1 mM) enhanced calcium ionophore (Br-A23187)- and tert-butylhydroperoxide (t-BuOOH)-induced cell death, which was blocked or delayed by cyclosporin A (CsA, 2 microM), a specific inhibitor of the MPT. In hepatocyte apoptosis induced by tumor necrosis factor-alpha (TNF-alpha), salicylate accelerated cell killing after low-dose TNF-alpha (1 ng/ml), which by itself induced little apoptosis. Salicylate enhancement of apoptosis was associated with onset of the MPT and accelerated caspase 3 activation. Salicylate also augmented killing of MCF-7 human breast tumor cells by etoposide and PLC/PRF/5 human hepatoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In conclusion, salicylate potentiates both necrotic and apoptotic cell killing by promoting onset of the MPT. Enhancement by salicylate of MPT-dependent apoptosis may play a role in protection by aspirin and other nonsteroidal anti-inflammatory drugs against colon, lung, and breast cancer. 相似文献
102.
Dural repair using acellular human dermis: experience with 200 cases: technique assessment 总被引:47,自引:0,他引:47
Warren WL Medary MB Dureza CD Bellotte JB Flannagan PP Oh MY Fukushima T 《Neurosurgery》2000,46(6):1391-1396
OBJECTIVE: Many craniotomies require a watertight dural closure. When primary dural repair is not possible, a graft is necessary. Autograft material is not always easily accessible or available, necessitating the use of other material. We performed 200 craniotomies using an acellular human dermal graft (AlloDerm; LifeCell Corp., The Woodlands, TX) to determine its suitability as a dural substitute. METHODS: From June 1996 through March 1998, all patients at Allegheny General Hospital who required a dural substitute graft and in whom autograft harvest was impractical or impossible received the acellular dermal autograft. The running suture technique was used to form a watertight seal. RESULTS: After follow-up for a minimum of 1 year, seven patients have required subsequent surgery. Three patients developed cerebrospinal fluid leaks that were repaired without removing the dermal graft. Four patients developed wound infections that required debridement. In each patient, the graft seemed to be uninvolved in the infectious process and was left in place. The patients were administered antibiotics postoperatively, and there have been no recurrent infections. No adhesion formation or scarring was noted around or underneath the graft in any patient. CONCLUSION: AlloDerm is a reasonable alternative to the available dural graft materials. Its handling characteristics are similar to those of dura, it is biologically inert, and it does not produce adhesion formation. 相似文献
103.
Glenn Liu David R Gandara Primo N Lara Derek Raghavan James H Doroshow Przemyslaw Twardowski Philip Kantoff William Oh KyungMann Kim George Wilding 《Clinical cancer research》2004,10(3):924-928
PURPOSE: Flavopiridol is a cyclin-dependent kinase inhibitor with preclinical activity against prostate cancer cell lines. A Phase II trial was conducted to determine the activity of flavopiridol in patients with metastatic hormone-refractory prostate cancer. EXPERIMENTAL DESIGN: A total of 36 patients was enrolled from several institutions and treated with a 72-h continuous infusion of flavopiridol every 14 days at the eventual starting dose of 40 mg/m(2)/day. Dose escalation up to 60 mg/m(2)/day was permitted if no significant toxicity was observed. Responses were assessed every 12 weeks. Only those patients completing four courses of the 72-h infusion were considered evaluable for response because the primary objective was to determine progression-free survival at 6 months given the cytostatic nature of the agent. RESULTS: This study was conducted in a two-stage fashion. During the first stage, at least 20 evaluable patients needed to be enrolled to assess response. There were 22 of 36 patients evaluable for response. No objective responses were observed. Only 4 patients had stable disease for 16, 26, 29, and 48 weeks, respectively, stopping the trial by design as only 3 of 22 (14%) of the patients met the 6-month progression-free survival end point. The most common toxicities were diarrhea (grade 1 and 2) and nausea, although some grade 3 and 4 diarrhea (11 and 6%, respectively) were evident. CONCLUSIONS: Flavopiridol has disappointing single-agent activity in hormone-refractory prostate cancer when administered at this dose and schedule. Its use in prostate cancer should be reserved for evaluation in combination therapies or alternative schedules. 相似文献
104.
Young Ho Yun Chang Geol Lee Si-young Kim Sang-wook Lee Dae Seog Heo Jun Suk Kim Keun Seok Lee Young Seon Hong Jung Suk Lee Chang Hoon You 《Journal of clinical oncology》2004,22(2):307-314
PURPOSE:To ascertain the attitude of cancer patients and their families toward disclosure of terminal illness to the patient. PATIENTS AND METHODS: We constructed a questionnaire that included demographic and clinical information and delivered it to 758 consecutive individuals (433 cancer patients and 325 families that have a relative with cancer) at seven university hospitals and one national cancer center in Korea. RESULTS: 380 cancer patients and one member from each of 281 families that have a relative with cancer completed the questionnaire. Cancer patients were more likely than family members to believe that patients should be informed of the terminal illness (96.1% v 76.9%; P <.001). Fifty percent of the family members and 78.3% of the patients thought that the doctor in charge should be the one who informs the patient. Additionally, 71.7% of the patients and 43.6% of the family members thought that patients should be informed immediately after the diagnosis. Stepwise multiple logistic regression indicated that the patient group was more likely than the family group to want the patient to be informed of the terminal illness (odds ratio [OR], 9.76; 95% CI, 4.31 to 22.14), by the doctor (OR, 4.00; 95% CI, 2.61 to 6.11), and immediately after the diagnosis (OR, 3.64; 95% CI, 2.45 to 5.41). CONCLUSION: Our findings indicated that most cancer patients want to be informed if their illness is terminal, and physicians should realize that the patient and the family unit may differ in their attitude toward such a disclosure. Our results also reflect the importance of how information is given to the patient. 相似文献
105.
Expression of placental growth factor gene in lung cancer. 总被引:4,自引:0,他引:4
In Sook Woo Myung Jae Park Jae Ho Byun Young Seon Hong Kyung Shik Lee Young Suk Park Jung Ae Lee Young Iee Park Hye-Kyung Ahn 《Tumour biology》2004,25(1-2):1-6
Differences in the gene expression profiles in small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC) may explain their different clinical characteristics. The aims of this study were (1) to identify genes differentially expressed in SCLC and NSCLC using mRNA differential display, and (2) to determine the clinical relevance of such genes in lung cancer. RNA differential display using three SCLC and six non-SCLC cell lines was used to identify a differentially expressed gene. Differential expression of the gene was confirmed in additional lung cancer cell lines using RT-PCR. Immunohistochemical staining for the gene product was performed on paraffin-embedded tissue from lung cancer patients. We examined the relationship between the expression of the gene and clinical parameters, including disease stage, response to treatment and survival time. The placental growth factor (PGF) gene was identified as preferentially expressed in SCLC compared with NSCLC cell lines using mRNA differential display. Further analysis of 45 lung cancer cell lines using RT-PCR showed that the placental growth factor (PGF) gene was expressed in nine of 13 SCLC cell lines (69%) and five of 32 NSCLC cell lines (15.6%) (p < 0.001, Fisher's exact test). Immunohistochemistry using anti-PGF antibody on the paraffin blocks from lung cancer patients showed that PGF expression was significantly higher in SCLC than NSCLC tissue sections (32 vs. 5.6%, p = 0.041, Fisher's exact test). Expression of PGF protein did not correlate with disease stage, response to treatment or survival time in SCLC patients. The present study suggests there is higher expression of PGF in SCLC compared to NSCLC. It may be that higher expression of the angiogenic factor PGF contributes to differences between the progression of SCLC and NSCLC, especially in regard to the nature of SCLC metastasis. 相似文献
106.
107.
108.
Pulmonary tuberculosis in five young infants with nursery exposure: clinical, radiographic and CT findings 总被引:4,自引:0,他引:4
K.-I. Kim J. W. Lee Jae Hong Park Su Young Kim Hee Ju Park Phil Jo Choi Ki Nam Lee H. J. Kim Suk Hong Lee 《Pediatric radiology》1998,28(11):836-840
Clinical, radiographic (n = 5) and CT findings (n = 4) of five Korean infants ranging in age from 2 to 3 months with confirmed tuberculosis were retrospectively analysed.
All of the patients were symptomatic, anergic to tuberculin, and had a positive culture of Myobacterium tuberculosis in gastric aspirates. The probable source of infection was the hospital in which they were born. CT scans demonstrated hilar
and mediastinal lymph node enlargement with central low attenuation and peripheral enhancement in all cases. CT may be useful
in diagnosis by demonstrating characteristic adenopathy and disseminated disease in young infants.
Received: 2 September 1997 Accepted: 23 April 1998 相似文献
109.
Han DH Kwon OK Byun BJ Choi BY Choi CW Choi JU Choi SG Doh JO Han JW Jung S Kang SD Kim DJ Kim HI Kim HD Kim MC Kim SC Kim SC Kim Y Kwun BD Lee BG Lim YJ Moon JG Park HS Shin MS Song JH Suk JS Yim MB;Korean Society for Cerebrovascular Disease 《Acta neurochirurgica》2000,142(11):1263-73; discussion 1273-4
A co-operative study was conducted to determine the clinical characteristics of patients with moyamoya disease who were diagnosed and treated at neurosurgical institutes in Korea before 1995. Twenty-six hospitals contributed 505 cases and among them, the clinical characteristics of 334 patients with definite moyamoya disease were evaluated. The number of patients began to increase from the late 1980s, and after that approximately 20 patients were treated each year. There were two age peaks: from six to 15 and from 31 to 40 years of age. Haemorrhagic manifestations occurred in approximately 43% of the patients. The major clinical manifestations were haemorrhage in adults (62.4%) and ischaemia in children (61.2%). Overall 54.5% of the patients experienced decreased consciousness levels, mainly due to intracranial haemorrhage or cerebral infarction. In the patients with ischemic manifestations, the adult patients were more likely to have cerebral infarction than the pediatric patients (80% vs. 39%) and the pediatric patients were more likely to have TIA (61% vs. 25%). Thirty eight percent of the patients underwent bypass surgery and 53% of these procedures were performed bilaterally. Treatment policies, including indications for bypass surgery and commonly used drugs, were somewhat different according to the institution. Overall favorable outcome was 73%, and the most significant factor affecting poor outcome was haemorrhagic manifestation. This article describes the characteristics of 334 patients with moyamoya disease, who were diagnosed and treated at neurosurgical institutes in Korea before 1995. 相似文献
110.
Oh BR Sasaki M Perinchery G Ryu SB Park YI Carroll P Dahiya R 《The Journal of urology》2000,163(5):1584-1587
PURPOSE: Tumor necrosis factor-alpha (TNF-alpha) is involved in oncogenesis of several cancers. The purpose of this study was to investigate whether genotype changes of TNF-alpha promoter regions (-238, -308) and at the 488 region are associated with human prostate cancer. MATERIALS AND METHODS: The DNA from 73 cases of human prostate cancer was analyzed by allele-specific polymerase chain reaction to characterize the genotype changes of three regions of the TNF-alpha gene in prostate cancer patients. We also determined the genotype frequency in these patients. The relative risk of variant genotype was calculated by comparing with our previous data from healthy controls. RESULTS: Genetic changes were detected in 15.1% (11/73) of prostate cancer samples at 488 region of TNF-alpha. Seventy-three percent (53/73) of the patients showed genotype GA at -308 region of TNF-alpha. Genotype GA at 488 region in TNF-alpha was observed in 73% (53/73) of the cancer and 71% (52/73) of the normal tissue. The relative risks of incidence for prostate cancer was 14-fold higher in people with genotype GA at -308 region of TNF-alpha. The relative incidence for prostate cancer was a 17-fold higher in-patient with genotype GA at 488 region of TNF-alpha. Genotype GA at -308 of TNF-alpha was related to higher clinical tumor stage of prostate cancer than genotype G (p <0.05). CONCLUSIONS: The present study demonstrates, for the first time, that the genotype changes in -308 and 488 regions of TNF-alpha are associated with prostate cancer. 相似文献